Cognition Therapeutics (NASDAQ:CGTX) is a biopharmaceutical company focused on the discovery and development of innovative therapies for neurodegenerative diseases. Its main projects target the underlying pathophysiology of diseases such as Alzheimer's, showcasing a commitment to addressing significant unmet medical needs in the aging population. The company's objectives revolve around advancing its lead candidate, CT1812, through clinical trials, aiming to demonstrate its potential in modifying the course of Alzheimer’s disease and related conditions. By leveraging its proprietary drug discovery platform, Cognition Therapeutics is dedicated to expanding its pipeline to encompass treatments for other central nervous system disorders, aspiring to improve the lives of patients worldwide through groundbreaking science and medicine.